AKT1S1, AKT1 substrate 1, 84335

N. diseases: 55; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.040 Biomarker phenotype BEFREE Expression of proline-rich Akt-substrate PRAS40 in cell survival pathway and carcinogenesis. 16174443 2005
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.030 AlteredExpression group BEFREE The expression of PRAS40, Akt, Raf and 14-3-3 in normal cells and cancer cell lines was determined by Western blot. 16174443 2005
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.030 Biomarker phenotype BEFREE To study the expression of proline-rich Akt-substrate PRAS40 in the cell survival pathway and tumor progression. 16174443 2005
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.030 AlteredExpression group BEFREE The expression of PRAS40, Akt, Raf and 14-3-3 in normal cells and cancer cell lines was determined by Western blot. 16174443 2005
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.020 Biomarker disease BEFREE In the breast cancer model (MCF10A/MCF7) and lung cancer model (BEAS/H1198/H1170) we also found the same result: PRAS40 was constitutively active in H1198/H1170 and MCF7 pre-malignant and malignant cancer cells, but weakly expressed in MCF10A and BEAS normal cell. 16174443 2005
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma 		0.020 AlteredExpression disease BEFREE We also discussed PRAS40 activity in other NSCLC cell lines. 16174443 2005
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.020 Biomarker disease BEFREE In the breast cancer model (MCF10A/MCF7) and lung cancer model (BEAS/H1198/H1170) we also found the same result: PRAS40 was constitutively active in H1198/H1170 and MCF7 pre-malignant and malignant cancer cells, but weakly expressed in MCF10A and BEAS normal cell. 16174443 2005
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.010 Biomarker disease BEFREE In the breast cancer model (MCF10A/MCF7) and lung cancer model (BEAS/H1198/H1170) we also found the same result: PRAS40 was constitutively active in H1198/H1170 and MCF7 pre-malignant and malignant cancer cells, but weakly expressed in MCF10A and BEAS normal cell. 16174443 2005
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.010 Biomarker disease BEFREE In the breast cancer model (MCF10A/MCF7) and lung cancer model (BEAS/H1198/H1170) we also found the same result: PRAS40 was constitutively active in H1198/H1170 and MCF7 pre-malignant and malignant cancer cells, but weakly expressed in MCF10A and BEAS normal cell. 16174443 2005
CUI: C1306460
Disease: Primary malignant neoplasm of lung
Primary malignant neoplasm of lung 		0.010 Biomarker disease BEFREE In the breast cancer model (MCF10A/MCF7) and lung cancer model (BEAS/H1198/H1170) we also found the same result: PRAS40 was constitutively active in H1198/H1170 and MCF7 pre-malignant and malignant cancer cells, but weakly expressed in MCF10A and BEAS normal cell. 16174443 2005
CUI: C0035126
Disease: Reperfusion Injury
Reperfusion Injury 		0.300 Biomarker disease CTD_human Modulation of proline-rich akt substrate survival signaling pathways by oxidative stress in mouse brains after transient focal cerebral ischemia. 16397181 2006
CUI: C0025202
Disease: melanoma
melanoma 		0.040 Biomarker disease BEFREE PRAS40 deregulates apoptosis in malignant melanoma. 17440074 2007
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.040 Biomarker group BEFREE Targeting PRAS40 or upstream Akt3 similarly reduced anchorage-independent growth in culture and inhibited tumor development in mice. 17440074 2007
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.040 Biomarker phenotype BEFREE In this study, PRAS40 was identified as an Akt3 substrate that deregulated apoptosis to promote melanoma tumorigenesis. 17440074 2007
CUI: C0018552
Disease: Hamartoma
Hamartoma 		0.010 Biomarker disease LHGDN These findings identify PRAS40 as an important regulator of insulin sensitivity of the Akt-mTOR pathway and a potential target for the treatment of cancers, insulin resistance and hamartoma syndromes. 17277771 2007
CUI: C0007785
Disease: Cerebral Infarction
Cerebral Infarction 		0.010 Biomarker disease BEFREE A proline-rich Akt substrate, PRAS40, has been characterized, and an increase in phospho-PRAS40 (pPRAS40) is neuroprotective after transient focal cerebral ischemia. 17457363 2008
CUI: C0017638
Disease: Glioma
Glioma 		0.010 PosttranslationalModification disease BEFREE Forty-five LGG tumor specimens from newly diagnosed patients were analyzed for methylation of the putative 5'-promoter region of PTEN using methylation-specific PCR as well as phosphorylation of S6 and PRAS40 and expression of PTEN protein using immunohistochemistry. 19705067 2010
CUI: C0022665
Disease: Kidney Neoplasm
Kidney Neoplasm 		0.010 AlteredExpression disease BEFREE Finally, it was observed that CNI treatment increased the expression of phosho-PRAS40 in renal tumor tissues in vivo. 21886838 2011
CUI: C0740457
Disease: Malignant neoplasm of kidney
Malignant neoplasm of kidney 		0.010 AlteredExpression disease BEFREE Together, the phosphorylation of PRAS40 is critical for the activation of mTOR in CNI-induced VEGF overexpression and renal cancer progression. 21886838 2011
CUI: C1378703
Disease: Renal carcinoma
Renal carcinoma 		0.010 AlteredExpression disease BEFREE Together, the phosphorylation of PRAS40 is critical for the activation of mTOR in CNI-induced VEGF overexpression and renal cancer progression. 21886838 2011
CUI: C3267003
Disease: Vascular endothelial growth factor overexpression
Vascular endothelial growth factor overexpression 		0.010 AlteredExpression disease BEFREE Together, the phosphorylation of PRAS40 is critical for the activation of mTOR in CNI-induced VEGF overexpression and renal cancer progression. 21886838 2011
CUI: C0553580
Disease: Ewings sarcoma
Ewings sarcoma 		0.010 Biomarker disease BEFREE PRAS40 is a functionally critical target for EWS repression in Ewing sarcoma. 22241085 2012
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction 		0.010 Biomarker disease BEFREE In comparison, preferentially shifting toward mTORC2 signaling by inhibition of mTORC1 with PRAS40 led to decreased cardiomyocyte apoptosis and tissue damage after myocardial infarction. 24008870 2013
CUI: C0020459
Disease: Hyperinsulinism
Hyperinsulinism 		0.010 AlteredExpression disease BEFREE Finally, over-expression of WT-PRAS40 reversed hyperinsulinemia-induced insulin resistance. 24576065 2014
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.040 AlteredExpression group BEFREE Fate mapping studies following transient expression of PRAS40 demonstrated that mTORC1(low) T cells made no contribution to initial tumor control but instead survived to become memory cells proficient in generating recall immunity. 25904681 2015